San Francisco, CA, United States of America

Shelley Suggett


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2003-2008

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Shelley Suggett in Coagulation Disorders

Introduction

Shelley Suggett is a prominent inventor based in San Francisco, CA (US), known for her significant contributions to the field of medical science. With a total of 3 patents, her work primarily focuses on methods for treating coagulopathic or thrombotic disorders.

Latest Patents

Among her latest patents, one notable invention is related to the methods of treating coagulopathic or thrombotic disorders. This invention provides for the isolation, identification, synthesis, expression, and purification of antibodies reactive with factor IX (FIX) and factor IXa (IXa). In particular aspects, the invention offers human antibodies that are reactive with the human FIX Gla domain. Additionally, it provides compositions, especially pharmaceutical compositions, articles of manufacture, and methods for inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation. Another significant patent is for human anti-factor IX/IXa antibodies, which shares similar methodologies and applications as her previous work.

Career Highlights

Shelley Suggett is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. Her work at Genentech has allowed her to contribute to groundbreaking research in the field of coagulation disorders.

Collaborations

Some of her notable coworkers include Camellia W Adams and Brigitte Devaux, who have collaborated with her on various projects within the company.

Conclusion

Shelley Suggett's innovative work in the field of coagulation disorders has led to significant advancements in medical treatments. Her contributions continue to impact the healthcare industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…